Global Crispr Genomic Cure Market

Crispr Genomic Cure Comprehensive Study by Application (Biomedical, Agricultural), Disease (Cancer, Blood disorders, Blindness, AIDS, Cystic fibrosis, Muscular dystrophy, Huntington's disease, Covid-19), End Use (Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, Contract Research Organizations (CROs)) Players and Region - Global Market Outlook to 2028

Crispr Genomic Cure Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 20.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Crispr Genomic Cure Market Scope
CRISPR Genome editing is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome. Several approaches to genome editing have been developed. A recent one is known as CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate, and more efficient than other existing genome editing methods.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca plc. (United Kingdom), Addgene (United States), Caribou Biosciences, Inc. (United States), Cellectis, CRISPR Therapeutics (France), Editas Medicine, Inc. (United States), eGenesis (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Horizon Discovery Group plc (United Kingdom), GenScript (United States) and Danaher Corporation (United States)
CAGR20.9%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

AstraZeneca plc. (United Kingdom), Addgene (United States), Caribou Biosciences, Inc. (United States), Cellectis, CRISPR Therapeutics (France), Editas Medicine, Inc. (United States), eGenesis (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Horizon Discovery Group plc (United Kingdom), GenScript (United States) and Danaher Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Intellia Therapeutics, Inc. (United States), Lonza (Switzerland) and Intellia Therapeutics, Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Crispr Genomic Cure market by Type , by Application (Biomedical and Agricultural) and Region with country level break-up.

On the basis of geography, the market of Crispr Genomic Cure has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In November 2020, PerkinElmer acquired Cell Engineering Company Horizon Discovery. This acquisition helps the company expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools
On 21 June 2021, The product launch marks QIAGEN’s dedicated solutions specific to the fast-growing field of CRISPR technology used for editing genomes and modifying gene function. Short for “clustered regularly interspaced short palindromic repeats,” CRISPR has a host of potential applications, from correcting genetic defects, treating and preventing the spread of diseases, and accelerating drug discovery and biomedical research. The new products add to the range of QIAGEN products that could also be used for CRISPR research such as the QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits. and On 30 March 2021, Scientists at UC San Francisco, UC Berkeley, and UCLA received U.S. Food and Drug Administration approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient’s own blood-forming stem cells.
A committee formed in the aftermath of a scandal has advised the World Health Organization (WHO) to take the lead in efforts to regulate genome editing on a global scale. The WHO should assist governments in coordinating their national regulations, according to the advisers, and genome editing should not yet be used to make changes that can be passed down to future generations.

Influencing Trend:
Advancement in CRISPR Genomic Cure

Market Growth Drivers:
Prevalence of Genetic Disorders and Use of Genome Editing and Government and Private Funding

Challenges:
Fierce Competitive Pressure

Restraints:
Occurs Side Effects Severe Muscle Weakness and Spasms, Severe Vomiting, Breathing Issues, Seizures, and Other Symptoms

Opportunities:
High Governmental Healthcare Expenditures and Expanding Gene and Cell Therapy Area

Key Target Audience
Crispr Genomic Cure Manufactures, New Entrants and Investors, Crispr Genomic Cure Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Application
  • Biomedical
  • Agricultural
By Disease
  • Cancer
  • Blood disorders
  • Blindness
  • AIDS
  • Cystic fibrosis
  • Muscular dystrophy
  • Huntington's disease
  • Covid-19

By End Use
  • Biotechnology & Pharmaceutical Companies
  • Academics & Government Research Institutes
  • Contract Research Organizations (CROs)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Genetic Disorders and Use of Genome Editing
      • 3.2.2. Government and Private Funding
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Advancement in CRISPR Genomic Cure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Crispr Genomic Cure, by Application, Disease, End Use and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Crispr Genomic Cure (Value)
      • 5.2.1. Global Crispr Genomic Cure by: Application (Value)
        • 5.2.1.1. Biomedical
        • 5.2.1.2. Agricultural
      • 5.2.2. Global Crispr Genomic Cure by: Disease (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Blood disorders
        • 5.2.2.3. Blindness
        • 5.2.2.4. AIDS
        • 5.2.2.5. Cystic fibrosis
        • 5.2.2.6. Muscular dystrophy
        • 5.2.2.7. Huntington's disease
        • 5.2.2.8. Covid-19
      • 5.2.3. Global Crispr Genomic Cure by: End Use (Value)
        • 5.2.3.1. Biotechnology & Pharmaceutical Companies
        • 5.2.3.2. Academics & Government Research Institutes
        • 5.2.3.3. Contract Research Organizations (CROs)
      • 5.2.4. Global Crispr Genomic Cure Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Crispr Genomic Cure: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Addgene (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Caribou Biosciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cellectis, CRISPR Therapeutics (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Editas Medicine, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. EGenesis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Horizon Discovery Group plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GenScript (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Danaher Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Crispr Genomic Cure Sale, by Application, Disease, End Use and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Crispr Genomic Cure (Value)
      • 7.2.1. Global Crispr Genomic Cure by: Application (Value)
        • 7.2.1.1. Biomedical
        • 7.2.1.2. Agricultural
      • 7.2.2. Global Crispr Genomic Cure by: Disease (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Blood disorders
        • 7.2.2.3. Blindness
        • 7.2.2.4. AIDS
        • 7.2.2.5. Cystic fibrosis
        • 7.2.2.6. Muscular dystrophy
        • 7.2.2.7. Huntington's disease
        • 7.2.2.8. Covid-19
      • 7.2.3. Global Crispr Genomic Cure by: End Use (Value)
        • 7.2.3.1. Biotechnology & Pharmaceutical Companies
        • 7.2.3.2. Academics & Government Research Institutes
        • 7.2.3.3. Contract Research Organizations (CROs)
      • 7.2.4. Global Crispr Genomic Cure Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Crispr Genomic Cure: by Application(USD Million)
  • Table 2. Crispr Genomic Cure Biomedical , by Region USD Million (2017-2022)
  • Table 3. Crispr Genomic Cure Agricultural , by Region USD Million (2017-2022)
  • Table 4. Crispr Genomic Cure: by Disease(USD Million)
  • Table 5. Crispr Genomic Cure Cancer , by Region USD Million (2017-2022)
  • Table 6. Crispr Genomic Cure Blood disorders , by Region USD Million (2017-2022)
  • Table 7. Crispr Genomic Cure Blindness , by Region USD Million (2017-2022)
  • Table 8. Crispr Genomic Cure AIDS , by Region USD Million (2017-2022)
  • Table 9. Crispr Genomic Cure Cystic fibrosis , by Region USD Million (2017-2022)
  • Table 10. Crispr Genomic Cure Muscular dystrophy , by Region USD Million (2017-2022)
  • Table 11. Crispr Genomic Cure Huntington's disease , by Region USD Million (2017-2022)
  • Table 12. Crispr Genomic Cure Covid-19 , by Region USD Million (2017-2022)
  • Table 13. Crispr Genomic Cure: by End Use(USD Million)
  • Table 14. Crispr Genomic Cure Biotechnology & Pharmaceutical Companies , by Region USD Million (2017-2022)
  • Table 15. Crispr Genomic Cure Academics & Government Research Institutes , by Region USD Million (2017-2022)
  • Table 16. Crispr Genomic Cure Contract Research Organizations (CROs) , by Region USD Million (2017-2022)
  • Table 17. South America Crispr Genomic Cure, by Country USD Million (2017-2022)
  • Table 18. South America Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 19. South America Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 20. South America Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 21. Brazil Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 22. Brazil Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 23. Brazil Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 24. Argentina Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 25. Argentina Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 26. Argentina Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 27. Rest of South America Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 29. Rest of South America Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 30. Asia Pacific Crispr Genomic Cure, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 33. Asia Pacific Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 34. China Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 35. China Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 36. China Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 37. Japan Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 38. Japan Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 39. Japan Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 40. India Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 41. India Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 42. India Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 43. South Korea Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 44. South Korea Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 45. South Korea Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 46. Australia Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 47. Australia Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 48. Australia Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 52. Europe Crispr Genomic Cure, by Country USD Million (2017-2022)
  • Table 53. Europe Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 54. Europe Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 55. Europe Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 56. Germany Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 57. Germany Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 58. Germany Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 59. France Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 60. France Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 61. France Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 62. Italy Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 63. Italy Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 64. Italy Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 65. United Kingdom Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 66. United Kingdom Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 67. United Kingdom Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 68. Netherlands Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 69. Netherlands Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 70. Netherlands Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 71. Rest of Europe Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 72. Rest of Europe Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 73. Rest of Europe Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 74. MEA Crispr Genomic Cure, by Country USD Million (2017-2022)
  • Table 75. MEA Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 76. MEA Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 77. MEA Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 78. Middle East Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 79. Middle East Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 80. Middle East Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 81. Africa Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 82. Africa Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 83. Africa Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 84. North America Crispr Genomic Cure, by Country USD Million (2017-2022)
  • Table 85. North America Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 86. North America Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 87. North America Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 88. United States Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 89. United States Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 90. United States Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 91. Canada Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 92. Canada Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 93. Canada Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 94. Mexico Crispr Genomic Cure, by Application USD Million (2017-2022)
  • Table 95. Mexico Crispr Genomic Cure, by Disease USD Million (2017-2022)
  • Table 96. Mexico Crispr Genomic Cure, by End Use USD Million (2017-2022)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Crispr Genomic Cure: by Application(USD Million)
  • Table 108. Crispr Genomic Cure Biomedical , by Region USD Million (2023-2028)
  • Table 109. Crispr Genomic Cure Agricultural , by Region USD Million (2023-2028)
  • Table 110. Crispr Genomic Cure: by Disease(USD Million)
  • Table 111. Crispr Genomic Cure Cancer , by Region USD Million (2023-2028)
  • Table 112. Crispr Genomic Cure Blood disorders , by Region USD Million (2023-2028)
  • Table 113. Crispr Genomic Cure Blindness , by Region USD Million (2023-2028)
  • Table 114. Crispr Genomic Cure AIDS , by Region USD Million (2023-2028)
  • Table 115. Crispr Genomic Cure Cystic fibrosis , by Region USD Million (2023-2028)
  • Table 116. Crispr Genomic Cure Muscular dystrophy , by Region USD Million (2023-2028)
  • Table 117. Crispr Genomic Cure Huntington's disease , by Region USD Million (2023-2028)
  • Table 118. Crispr Genomic Cure Covid-19 , by Region USD Million (2023-2028)
  • Table 119. Crispr Genomic Cure: by End Use(USD Million)
  • Table 120. Crispr Genomic Cure Biotechnology & Pharmaceutical Companies , by Region USD Million (2023-2028)
  • Table 121. Crispr Genomic Cure Academics & Government Research Institutes , by Region USD Million (2023-2028)
  • Table 122. Crispr Genomic Cure Contract Research Organizations (CROs) , by Region USD Million (2023-2028)
  • Table 123. South America Crispr Genomic Cure, by Country USD Million (2023-2028)
  • Table 124. South America Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 125. South America Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 126. South America Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 127. Brazil Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 128. Brazil Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 129. Brazil Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 130. Argentina Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 131. Argentina Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 132. Argentina Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 133. Rest of South America Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 134. Rest of South America Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 135. Rest of South America Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 136. Asia Pacific Crispr Genomic Cure, by Country USD Million (2023-2028)
  • Table 137. Asia Pacific Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 138. Asia Pacific Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 139. Asia Pacific Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 140. China Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 141. China Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 142. China Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 143. Japan Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 144. Japan Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 145. Japan Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 146. India Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 147. India Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 148. India Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 149. South Korea Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 150. South Korea Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 151. South Korea Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 152. Australia Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 153. Australia Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 154. Australia Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 155. Rest of Asia-Pacific Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 158. Europe Crispr Genomic Cure, by Country USD Million (2023-2028)
  • Table 159. Europe Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 160. Europe Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 161. Europe Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 162. Germany Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 163. Germany Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 164. Germany Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 165. France Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 166. France Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 167. France Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 168. Italy Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 169. Italy Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 170. Italy Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 171. United Kingdom Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 172. United Kingdom Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 173. United Kingdom Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 174. Netherlands Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 175. Netherlands Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 176. Netherlands Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 177. Rest of Europe Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 178. Rest of Europe Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 179. Rest of Europe Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 180. MEA Crispr Genomic Cure, by Country USD Million (2023-2028)
  • Table 181. MEA Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 182. MEA Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 183. MEA Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 184. Middle East Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 185. Middle East Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 186. Middle East Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 187. Africa Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 188. Africa Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 189. Africa Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 190. North America Crispr Genomic Cure, by Country USD Million (2023-2028)
  • Table 191. North America Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 192. North America Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 193. North America Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 194. United States Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 195. United States Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 196. United States Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 197. Canada Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 198. Canada Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 199. Canada Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 200. Mexico Crispr Genomic Cure, by Application USD Million (2023-2028)
  • Table 201. Mexico Crispr Genomic Cure, by Disease USD Million (2023-2028)
  • Table 202. Mexico Crispr Genomic Cure, by End Use USD Million (2023-2028)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Crispr Genomic Cure: by Application USD Million (2017-2022)
  • Figure 5. Global Crispr Genomic Cure: by Disease USD Million (2017-2022)
  • Figure 6. Global Crispr Genomic Cure: by End Use USD Million (2017-2022)
  • Figure 7. South America Crispr Genomic Cure Share (%), by Country
  • Figure 8. Asia Pacific Crispr Genomic Cure Share (%), by Country
  • Figure 9. Europe Crispr Genomic Cure Share (%), by Country
  • Figure 10. MEA Crispr Genomic Cure Share (%), by Country
  • Figure 11. North America Crispr Genomic Cure Share (%), by Country
  • Figure 12. Global Crispr Genomic Cure share by Players 2022 (%)
  • Figure 13. Global Crispr Genomic Cure share by Players (Top 3) 2022(%)
  • Figure 14. Global Crispr Genomic Cure share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 18. Addgene (United States) Revenue, Net Income and Gross profit
  • Figure 19. Addgene (United States) Revenue: by Geography 2022
  • Figure 20. Caribou Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Caribou Biosciences, Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Cellectis, CRISPR Therapeutics (France) Revenue, Net Income and Gross profit
  • Figure 23. Cellectis, CRISPR Therapeutics (France) Revenue: by Geography 2022
  • Figure 24. Editas Medicine, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Editas Medicine, Inc. (United States) Revenue: by Geography 2022
  • Figure 26. EGenesis (United States) Revenue, Net Income and Gross profit
  • Figure 27. EGenesis (United States) Revenue: by Geography 2022
  • Figure 28. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 30. Horizon Discovery Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Horizon Discovery Group plc (United Kingdom) Revenue: by Geography 2022
  • Figure 32. GenScript (United States) Revenue, Net Income and Gross profit
  • Figure 33. GenScript (United States) Revenue: by Geography 2022
  • Figure 34. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Danaher Corporation (United States) Revenue: by Geography 2022
  • Figure 36. Global Crispr Genomic Cure: by Application USD Million (2023-2028)
  • Figure 37. Global Crispr Genomic Cure: by Disease USD Million (2023-2028)
  • Figure 38. Global Crispr Genomic Cure: by End Use USD Million (2023-2028)
  • Figure 39. South America Crispr Genomic Cure Share (%), by Country
  • Figure 40. Asia Pacific Crispr Genomic Cure Share (%), by Country
  • Figure 41. Europe Crispr Genomic Cure Share (%), by Country
  • Figure 42. MEA Crispr Genomic Cure Share (%), by Country
  • Figure 43. North America Crispr Genomic Cure Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca plc. (United Kingdom)
  • Addgene (United States)
  • Caribou Biosciences, Inc. (United States)
  • Cellectis, CRISPR Therapeutics (France)
  • Editas Medicine, Inc. (United States)
  • eGenesis (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Horizon Discovery Group plc (United Kingdom)
  • GenScript (United States)
  • Danaher Corporation (United States)
Additional players considered in the study are as follows:
Intellia Therapeutics, Inc. (United States) , Lonza (Switzerland) , Intellia Therapeutics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 213 Pages 57 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Crispr Genomic Cure Market Quantitative research analysis
Global Crispr Genomic Cure Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Crispr Genomic Cure Market are by end use application [Biomedical and Agricultural].
The Crispr Genomic Cure Market is gaining popularity and expected to see strong valuation by 2028.
  • Prevalence of Genetic Disorders and Use of Genome Editing
  • Government and Private Funding

Know More About Global Crispr Genomic Cure Market Report?

Have a Query? Click Here

Other Related Reports

Microcarrier System Comprehensive Study by Type (Consumables (Media, Reagents, Microcarriers), Equipment (Bioreactors, Culture Vessels, Filtration and Separation Equipment, Cell Counters)), Applicati...
$ 3750
High Content Analysis Systems Comprehensive Study by Type (Instruments, Consumables, Software, Services, Accessories), Application (Target Identification & Validation, Toxicity Studies, Primary Scree...
$ 3750
Protein Electrophoresis Comprehensive Study by Application (Research, Process Validation, Diagnostics, Quality Control, Others), Category (Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophore...
$ 3650
Plant-based Vaccines Comprehensive Study by Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, Immunocontraceptive Vaccines), Application (Infectious Diseases, Anti-Cancer, Covid19, Others)...
$ 3450
Bioprocessing Bags Comprehensive Study by Type (D Bags, 3D Bags, Wave / Rocker Bags, Single Use Mixing System, Filter Bag System), End Users (Bioprocessing Laboratories, Hospitals, Biopharmaceutical ...
$ 3750
Triglycerides Testing Reagents Comprehensive Study by Application (Hospitals, Specialty Clinics, Diagnostic Centers), Triglyceride Causes (Lack Of Exercise, Being Overweight, Smoking Cigarettes, Con...
$ 3450